Health Cor Management, L.P. Biomarin Pharmaceutical Inc Transaction History

Health Cor Management, L.P.

$106 Million
Q4 2022

A detailed history of Health Cor Management, L.P. transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Health Cor Management, L.P. holds 367,765 shares of BMRN stock, worth $24.1 Million. This represents 35.97% of its overall portfolio holdings.

Number of Shares

367,765

Previous 759,038 51.55%

Holding current value

$24.1 Million

Previous $64.3 Million 40.85%

% of portfolio

35.97%

Previous 8.05%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$80.93 - $108.63 $31.7 Million - $42.5 Million	-391,273 Reduced 51.55%	367,765 $38.1 Million
Q3 2022 Nov 14, 2022	BUY	$82.16 - $96.94 $1.49 Million - $1.75 Million	18,090 Added 2.44%	759,038 $64.3 Million
Q2 2022 Aug 15, 2022	SELL	$71.48 - $86.85 $2.01 Million - $2.44 Million	-28,068 Reduced 3.65%	740,948 $61.4 Million
Q1 2022 May 16, 2022	BUY	$74.28 - $92.69 $45.3 Million - $56.5 Million	609,696 Added 382.69%	769,016 $59.3 Million
Q4 2021 Feb 14, 2022	BUY	$71.72 - $91.47 $11.4 Million - $14.6 Million	159,320 New	159,320 $14.1 Million
Q2 2021 Aug 16, 2021	SELL	$75.51 - $84.79 $17.2 Million - $19.3 Million	-227,450 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$74.73 - $90.69 $391,585 - $475,215	5,240 Added 2.36%	227,450 $17.2 Million
Q4 2020 Feb 16, 2021	BUY	$72.61 - $90.2 $15.1 Million - $18.7 Million	207,610 Added 1421.99%	222,210 $19.5 Million
Q3 2020 Nov 16, 2020	BUY	$71.87 - $131.03 $1.05 Million - $1.91 Million	14,600 New	14,600 $1.11 Million

Others Institutions Holding BMRN

# of Institutions

637

Shares Held

177M

Call Options Held

2.01M

Put Options Held

1.28M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.2B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Health Cor Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Health Cor Management, L.P. with notifications on news.

Account

Health Cor Management, L.P. Biomarin Pharmaceutical Inc Transaction History